Alembic Pharmaceuticals gets 8 USFDA approvals in Q3FY24
时间:2024-06-26 08:12:59 阅读(143)
Alembic Pharmaceuticals Limited on Tuesday announced that it has received US Food & Drug Administration (USFDA) approvals on eight of its Abbreviated New Drug Application (ANDA) in Q3FY24.
The Company has received five final approvals that includes Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg and 1,600 mcg, Dapsone gel, 7.5%, Fluorouracil Injection USP 5g/100mL (50 mg/mL), Pharmacy Bulk Package (Vial), Carmustine for Injection USP 100 mg/vial (Single-dose Vial) and Acyclovir Cream, 5%. The Company has also received three tentative approvals that includes Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, Bromfenac Ophthalmic Solution, 0.07%., and Osimertinib Tablets, 40 mg and 80 mg.
Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg with brand name of Xarelto Tablets of Janssen Pharmaceuticals, Inc. Rivaroxaban tablets are indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also used for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), for the reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months. These tablets also used for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery and for the prophylaxis of venous thromboembolism (VTE) and VTE related death during hospitalization and post hospital discharge in adult patients admitted for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE and not at high risk of bleeding. These tablets also used in combination with aspirin, is indicated to reduce the risk of major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Dapsone gel, 7.5% with brand name of Aczone Gel of Almirall, LLC. Dapsone gel, 7.5% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Bromfenac Ophthalmic Solution, 0.07% with brand name of Prolensa Ophthalmic Solution of Bausch & Lomb Incorporated. Bromfenac ophthalmic solution 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Fluorouracil Injection USP, 5 g/100 mL (50 mg/mL), Pharmacy Bulk Package (Vial) with brand name of Adrucil Injection USP of Pharmcia and Upjohn. Fluorouracil is indicated for the treatment of patients with adenocarcinoma of the colon and rectum, breast, stomach and pancreas.
Carmustine for Injection USP, 100 mg/vial (Single-dose Vial) with brand name of BiCNU Injection of Avet Lifesciences Private Limited. Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. It is used in multiple myeloma in combination with prednisone. It is also used in relapsed or refractory Hodgkin’s lymphoma/Non-Hodgkin’s lymphoma in combination with other approved drugs.
Acyclovir Cream, 5% with brand name of Zovirax Cream of Bausch Health US, LLC. Acyclovir cream, 5% indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.
Osimertinib Tablets, 40 mg, and 80 mg with brand name of Tagrisso Tablets of AstraZeneca Pharmaceuticals LP. Osimertinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. It is also used in the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
猜你喜欢
- FII buying trends in India- With current resilience in domestic, global markets, will buying sustain-
- tions and academic institutions have computed logistics costs, which are widely quoted to stress the point that India is a country with high logistics costs.” In addition to the ones I mentioned earlier, NCAER cites three—Armstrong and Associates (2017), an estimate of 13% of GDP; CII (2015), an estimate of 10.9% of GVA; and NCAER (2019), an estimate of 8.9% of GVA. Clearly, there are variations in what is being measured and how. This new NCAER report uses supply and use tables. What does it find? In 2021-22, logistics costs had an estimated range of between 7.8% and 8.9%. In 2014-15, they had an estimated range of between 8.3% and 9.4%. There has been a decline over time (with a transient increase in 2017-18 and 2018-19). It cannot be anyone’s case that this new NCAER report is the last word on the subject. But it is a beginning, with a clear methodology. And two points emerge. First, logistics costs aren’t as bad as they are often made out to be. Second, they have declined over time (also evident from LPI).
Logistics, good or bad, are driven by the states and the commerce ministry has a LEADS (Logistics Ease Across Different States) report, based on perceptions. The 2023 version was released in December. Since states are heterogenous, in the reporting, they are divided into four groups—coastal, landlocked, north-east, and UTs. States that do well are called achievers. Nomenclature matters. Thus, states that are middling aren’t called average. They are called fast movers. States that are sub-par are called aspirers. Let me highlight coastal states, since 75% of export cargo is estimated to originate from them. Among coastal states, ones that do well are Andhra Pradesh, Gujarat, Karnataka, and Tamil Nadu. The ones that lag are Goa, Odisha, and West Bengal. While India’s logistics performance may have improved over time, that’s not true of every state. Some have slipped. Most states have a state-level logistics policy, including Goa and Odisha. West Bengal, bottom of the pecking order in the coastal category, doesn’t have one. To quote from LEADS 2023, “Looking ahead, the State (West Bengal) could benefit from formulating a State Logistics Master Plan and State Logistics Policy to drive efficiency improvements and facilitate investments within the logistics sector and undertake consultation with the logistics stakeholders for educating and informing them about the initiatives State is undertaking for the development and improvement of logistics sector.”
Logistics has been talked about for a long time and India has also focused on improving performance. We are now getting some precise data on measurement and quantification. That helps.
Bibek Debroy, chairman, EAC-PM. Views are personal.
- Gold Price Today, 4 July- Gold rises modestly on futures traders’ quick rebound; traders eye FOMC June meeting minutes
- Mandi prices of most items above new minimum support prices, only pulses cheaper
- Gold prices likely to trade sideways to down this week; resistance at Rs 50800, support at 49500 per 10 gram
- Finance Ministry finalises framework for sovereign green bonds
- Govt releases Rs 2,874 crore to PLI beneficiaries so far- Official
- Man Infra to redevelop property co-owned by Aamir Khan
- Long queues at petrol pumps as truckers’ protest against hit-and-run law affects supply